Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer
A Tecentriq regimen did not improve event-free survival in patients with triple-negative breast cancer.For patients with triple-negative breast cancer (TNBC), ...
Tag: tecentriq
FDA Approves Subcutaneous Tecentriq Formulation
FDA Approves Subcutaneous Tecentriq FormulationThe Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous injection, for ...
Tecentriq Plus Chemoradiation May Be Safe, Effective in Unresectable Stage 3 NSCLC
The disease control rate for patients with surgically unremovable NSCLC was 74.2% after 12 weeks of receiving neoadjuvant Tecentriq. Tecentriq ...